Eli Lilly (NY:LLY)

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

Today 10:01 EST

As of December 24, 2025, the pharmaceutical landscape is witnessing a pivotal shift in the treatment of chronic obesity. Novo Nordisk (NYSE: NVO), the Danish titan that pioneered the GLP-1 revolution,...

Topics Economy

Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook

Today 9:32 EST

Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗

Topics Economy Intellectual Property

December 23, 2025

Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗

Today 9:16 EST

Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage

Today 8:00 EST

Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and...

Via Newsfile

Top 5 US Healthcare Stocks By Market Value ↗

Today 4:06 EST

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗

Today 4:01 EST

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗

Today 3:45 EST

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Topics ETFs Stocks

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

Resilient Prosperity: Blowout Q3 GDP Growth Ignites Year-End Market Surge Amid 'No-Landing' Fears

December 23, 2025

The United States economy defied gravity in the third quarter of 2025, posting a staggering 4.3% annualized growth rate that has sent shockwaves through global financial markets. Released on December...

Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗

Topics Artificial Intelligence Bonds Economy

December 23, 2025

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

Via The Motley Fool

Topics Stocks

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

Topics Government

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

Topics Intellectual Property

December 23, 2025

BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for...

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus ↗

Topics Economy

December 23, 2025

Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus.

Via Benzinga

Topics ETFs

What's Going On With Eli Lilly Stock Today? ↗

December 23, 2025

Eli Lilly And Co (NASDAQ: LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector.

Via Benzinga

Thin Trading and High Hopes: Markets Eye a 'Santa Claus Rally' as 2025 Draws to a Close

December 23, 2025

As the sun sets on a volatile but ultimately record-breaking year, Wall Street has entered its final, holiday-shortened trading week of 2025. With the S&P 500 sitting at a historic peak of 6,904 as of...

Santa Claus Rally Solidifies as S&P 500 Secures Third Consecutive Winning Session Amid Economic Resilience

Topics Artificial Intelligence Economy Stocks

December 23, 2025

The U.S. equity markets continued their year-end ascent on Tuesday, December 23, 2025, as the S&P 500 (INDEXSP:.INX) notched its third consecutive winning session. This momentum, often referred to as...

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Topics Artificial Intelligence Bonds Economy

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

When Mega-cap tech fades, pharma takes spotlight: LLY and NVO are top picks for long-term growth with strong demand for GLP-1 treatments.

Topics Economy

Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback ↗

December 23, 2025

Via Benzinga

Nasdaq, S&P 500 Futures Tread Caution Ahead Of GDP, Confidence Data: Why NVO, ZIM, SIDU Are On Traders' Radar Today ↗

December 23, 2025

Eli Lilly currently trades at $1,061 and has been a dream stock for shareholders. It’s returned 541% since December 2020, blowing past the S&P 500’s 85.2% gain. The company has also beaten the index...

Topics Stocks

3 Reasons Investors Love Eli Lilly (LLY)

December 22, 2025

Via StockStory

Topics Stocks

Why Abivax Stock Was on Fire Today ↗

December 22, 2025

Investors were excited about the possibility of a buyout with a high price tag.

Via The Motley Fool

Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug ↗

December 22, 2025

The FDA approved a Wegovy pill as the first oral GLP-1 treatment for weight loss.

Via Investor's Business Daily

Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Loss ↗

December 22, 2025

The Danish drugmaker expects to launch the pill in the U.S. in January.

As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon...

The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Topics Economy Intellectual Property

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025